TP53 and cancer: Furthermore, dual inhibition of MDMX and MDM2 with a stapled α-helical peptide (ALRN-6924) exhibited marked antileukemic effects in vitro and in vivo, which support further testing of the dual inhibitor as a therapeutic approach in cancers with wild-type TP53 [96,97].